NCT-501 is primarily investigated for its potential therapeutic applications, particularly in the field of cancer research. It functions as a selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), an enzyme often overexpressed in cancer stem cells. By inhibiting ALDH1A1, NCT-501 aims to target and reduce the population of these stem cells, which are known to contribute to tumor growth, metastasis, and resistance to conventional treatments like chemotherapy and radiation. This makes it a promising candidate for combination therapies, where it could enhance the efficacy of existing cancer treatments. Additionally, research is exploring its role in addressing diseases where ALDH1A1 activity is implicated, such as certain types of fibrosis and neurodegenerative disorders. Its application is still largely in the experimental stage, with ongoing studies to evaluate its safety, efficacy, and potential clinical benefits.